NCT06963034: An ongoing trial by Neurocrine Biosciences
This trial is ongoing. It must report results 2 years, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06963034 |
|---|---|
| Title | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 8, 2025 |
| Completion date | Oct. 31, 2027 |
| Required reporting date | Oct. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |